Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc has demonstrated consistent revenue performance, with fourth quarter revenues anticipated to fall between $88.6 million and $90.6 million, representing a 12-15% year-over-year increase. The company is projected to outpace the broader aesthetics market, bolstered by an expanding market share and a focus on younger consumers who are increasingly receptive to aesthetic treatments. Additionally, Evolus has set an optimistic annual revenue forecast for 2026 in the range of $327 million to $337 million, which indicates a compound annual growth rate (CAGR) of 15-19% over the next three years, alongside a commitment to achieving sustainable profitability.

Evolus Inc has experienced a significant reduction in its long-term financial outlook, with management projecting total net revenue to fall between $450 million and $500 million, down from a prior estimate of $700 million. A decline in aesthetic sales, including an approximate 8% decrease through the third quarter of 2025, has raised concerns, especially as leading products like Botox and Juvederm have shown substantial year-over-year declines of around 14% and 20%, respectively. Additionally, weakened consumer sentiment due to economic pressures is expected to further dampen sales trends for both Jeuveau and Evolus's broader offerings through 2026.